Your browser doesn't support javascript.
loading
Efficacy of recombinant erythropoietin for the late treatment of anemia of prematurity in a level IV neonatal intensive care unit: a retrospective single-center cohort study.
Connolly, Jillian M; McClary, Jacquelyn D; Desai, Riddhi; Sundaram, Anupama; Neudecker, Mandy; Nock, Mary L; Ryan, Rita M; Marasch, Jaime L.
Afiliación
  • Connolly JM; UH Rainbow Babies & Children's Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. jillian.m.connolly@gmail.com.
  • McClary JD; UH Rainbow Babies & Children's Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
  • Desai R; UH Rainbow Babies & Children's Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
  • Sundaram A; UH Rainbow Babies & Children's Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
  • Neudecker M; UH Rainbow Babies & Children's Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
  • Nock ML; UH Rainbow Babies & Children's Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
  • Ryan RM; UH Rainbow Babies & Children's Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
  • Marasch JL; UH Rainbow Babies & Children's Hospital, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.
J Perinatol ; 44(6): 892-896, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38773216
ABSTRACT

OBJECTIVE:

To describe the population to which we administered recombinant erythropoietin and to determine the effectiveness of this treatment as quantified by the change in hematocrit. STUDY

DESIGN:

This retrospective chart review study included infants who received erythropoietin for the treatment of anemia of prematurity.

RESULTS:

There were 132 infants representing 162 unique treatment courses included in the study. The average duration of therapy was 9 days (±7) and 6 doses (±2). The average change in hematocrit (Hct) was 6.2% (SD 3.9%, p < 0.001). Rise in Hct was associated with a higher number of rEPO doses (p < 0.001) and higher postmenstrual age (p < 0.001). In our small cohort we did not find an association between the number of rEPO doses and retinopathy of prematurity (ROP) requiring treatment.

CONCLUSION:

Erythropoietin is safe and effective at treating anemia of prematurity as evidenced by a clinically and statistically significant increase in Hct from baseline.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Recombinantes / Recien Nacido Prematuro / Unidades de Cuidado Intensivo Neonatal / Eritropoyetina / Anemia Neonatal Límite: Female / Humans / Male / Newborn Idioma: En Revista: J Perinatol Asunto de la revista: PERINATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Recombinantes / Recien Nacido Prematuro / Unidades de Cuidado Intensivo Neonatal / Eritropoyetina / Anemia Neonatal Límite: Female / Humans / Male / Newborn Idioma: En Revista: J Perinatol Asunto de la revista: PERINATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos